Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NIC 002

Drug Profile

NIC 002

Alternative Names: Anti-nicotine immunotherapy - Cytos; Anti-nicotine virus-like particle vaccine - Cytos; CYT002-NicQβ; Immunodrug™ nicotine addiction vaccine - Cytos/Novartis; NIC002 vaccine; Nicotine-Qβ

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytos Biotechnology
  • Developer Cytos Biotechnology; Duke University; Wake Forest University School of Medicine
  • Class Smoking cessation therapies; Vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Smoking withdrawal

Most Recent Events

  • 23 Jan 2013 Novartis terminates its worldwide licence for NIC 002 and rights will revert back to Cytos Biotechnology
  • 31 Dec 2010 Phase-II clinical trials in Smoking withdrawal in USA (SC)
  • 21 Sep 2010 Phase II development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top